Jiangsu Hengrui Medicine Co., Ltd
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
Irinotecan Liposome in Combination With 5-FU/LV Versus 5-FU/LV in Second-line Therapy for Gemcitabine-Refractory Pancreatic Cancer
Phase 3
Completed
- Conditions
- Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy
- Interventions
- Drug: Placebo、5-Fluorouracil、Leucovorin
- First Posted Date
- 2021-10-12
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 298
- Registration Number
- NCT05074589
- Locations
- 🇨🇳
Qinhuai Medical Area, General Hospital of PLA Eastern Theater Command, Nanjing, Jiangsu, China
A Study to Evaluate the Efficacy and Safety of SHR8008 vs. Fluconazole in Subjects With Recurrent Vulvovaginal Candidiasis
- First Posted Date
- 2021-10-12
- Last Posted Date
- 2021-10-12
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 196
- Registration Number
- NCT05074602
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Clinical Study of Retagliptin Phosphate Combined With Metformin in the Treatment of Type 2 Diabetes
Phase 3
Active, not recruiting
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2021-09-23
- Last Posted Date
- 2023-07-10
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 174
- Registration Number
- NCT05054842
- Locations
- 🇨🇳
Beijing Hospital, Beijing, Beijing, China
A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies
Phase 1
Recruiting
- Conditions
- Advanced Malignancies
- Interventions
- Drug: HRS2300、 SHR-1316Drug: HRS2300、SHR-1701Drug: HRS2300、trametinibDrug: HRS2300、Almonertinib
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2021-11-02
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 345
- Registration Number
- NCT05048134
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
A Relative Bioavailability Study of Different Processes of SHR2554 Tablets in Healthy Adult Subjects
Phase 1
- Conditions
- Lymphoma
- Interventions
- Drug: New Process SHR2554 tablet、Former Process SHR2554 tabletDrug: Former Process SHR2554 tablet、New Process SHR2554 tablet
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2022-01-14
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT05049083
- Locations
- 🇨🇳
the Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
A Study of Human Substance Balance and Biotransformation of [14C]SHR0302
Phase 1
Completed
- Conditions
- Rheumatoid Arthritis (RA)
- Interventions
- Drug: SHR0302、[14C]SHR0302
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT05047341
- Locations
- 🇨🇳
the first affiliated hospital of Soochow University, Suzhou, Jiangsu, China
Pharmacokinetics Study of Famitinib Malate Capsules in Healthy Subjects
- First Posted Date
- 2021-09-16
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 70
- Registration Number
- NCT05046808
- Locations
- 🇨🇳
Xiangya Hospital Central South University, Changsha, Hunan, China
A Drug-drug Interaction Study of Famitinib Malate With a Proton Pump Inhibitor in Healthy Adult Subjects
Phase 1
Completed
- Conditions
- Tumor
- Interventions
- Drug: famitinib、omeprazole
- First Posted Date
- 2021-09-13
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT05041920
- Locations
- 🇨🇳
Zhongda Hospital, Affiliated to Southest University, Nanjing, Jiangsu, China
A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
Phase 3
Recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2021-09-13
- Last Posted Date
- 2022-11-17
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 450
- Registration Number
- NCT05042375
- Locations
- 🇨🇳
Shaoyang Central Hospital, Shaoyang, Hunan, China
🇨🇳Xiangyang Central Hospital, Xiangyang, Hubei, China
🇨🇳Hunan Cancer Hospital-Thoracic Medicine Department I, Changsha, Hunan, China
A Trial of SHR-1703 in Asthma
- First Posted Date
- 2021-09-13
- Last Posted Date
- 2023-04-25
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 23
- Registration Number
- NCT05042401
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China
© Copyright 2025. All Rights Reserved by MedPath